The increased risk of hospitalization due to myopathy, renal and hepatic adverse medical events has been identified in lipid-lowering drug users with co-administration of CYP3A4 inhibitors (RR = 6.01, 95 % CI: 2.08–17.38; RR = 2.29, 95 % CI: 1.62–3.23; and RR = 2.55, 95 % CI: 1.76–3.70, respectively) [24]. The gene discussed is CYP3A4; the disease is myopathy.